Showing results (151-160 of 296) with videos related to
Sort By:
Pageof 30
The Journal of Craniofacial Surgery|July 25, 2008
Prevention and management of hypertrophic scars and keloids after burns in childrenBrian Berman, Martha H Viera, Sadegh Amini, et al.Arthritis and Rheumatism|July 13, 2002
Psychological interventions for rheumatoid arthritis: a meta-analysis of randomized controlled trialsJohn A Astin, William Beckner, Karen Soeken, et al.International Journal of Dermatology|February 27, 2024
Demographics, clinical characteristics, and treatment patterns among keloid patients: United States Electronic Health Records (EHR) Database StudyAbisola Olopoenia, Yuji Yamaguchi, Elena Peeva, et al.Archives of Dermatological Research|December 5, 2024
Cross-sectional analysis reveals increased use of nonspecific terminology in reference to women dermatologists in patient reviews at academic centersMatthew D Viveiros, Michelle Huynh, Maria C Carrasco, et al.Journal of Drugs in Dermatology : JDD|August 3, 2007
A closer look at truncal acne vulgaris: prevalence, severity, and clinical significanceJames Q Del Rosso, Joseph B Bikowski, Eric Baum, et al.Heart Rhythm|April 23, 2026
Increased risk of lead transection and procedural complexity during extraction of thin-diameter, single filar pacemaker leadsAparna Sajja, Wissam Mekary, Jingwen Huang, et al.Journal of Drugs in Dermatology : JDD|August 2, 2024
Tildrakizumab Real-World Effectiveness and Safety Over 64 Weeks in Patients With Moderate-to-Severe Plaque PsoriasisJayme Heim, J Gabriel Vasquez, Tina Bhutani, et al.Journal of Drugs in Dermatology : JDD|February 2, 2011
Complete clearance is sustained for at least 12 months after treatment of actinic keratoses of the face or balding scalp via daily dosing with imiquimod 3.75% or 2.5% creamC William Hanke, Neil Swanson, Suzanne Bruce, et al.Cutis|December 26, 2006
Desoximetasone 0.25% and tacrolimus 0.1% ointments versus tacrolimus alone in the treatment of atopic dermatitisAdelaide A Hebert, John Koo, Joseph Fowler, et al.Journal of the American Academy of Dermatology|February 6, 2010
Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cyclesNeil Swanson, William Abramovits, Brian Berman, et al.Pageof 30